In particular, Kvistborg and colleagues showed that mo-DCs from CRC patients matured with the gold standard mix achieved significantly higher CD83, CD86, and CCR7 than mo-DCs matured with TNF-α alone [109]. The gene discussed is CD83; the disease is colorectal carcinoma.